Pfizer's respiratory syncytial virus (RSV) vaccine for pregnant women was not tied to a higher risk of pre-term or early births, according to a study published on Monday that analyzed real-world use of the shots.
The vaccine Abrysvo was approved by the U.S. Food and Drug Administration
last year for women in their second or third trimesters of pregnancy to prevent infections tied to RSV in babies in the first six months after birth.
